{
    "body": "Which two catechol-O-methyl transferase (COMT) inhibitors can be used for treatment of Parkinson disease?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15853578", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11147512", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11147511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15372589", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21164341", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19589043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12952501", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12588639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10733264", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8784230", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1933685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14741081", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10651109", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19198095"
    ], 
    "ideal_answer": [
        "Tolcapone (central and peripheral) and entacapone (peripheral) are catechol-O-methyl transferase inhibitors that are used for treatment of Parkinson disease."
    ], 
    "exact_answer": [
        [
            "tolcapone"
        ], 
        [
            "entacapone"
        ]
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010300", 
        "http://www.uniprot.org/uniprot/COMT_RAT", 
        "http://www.uniprot.org/uniprot/COMT_MOUSE", 
        "http://www.uniprot.org/uniprot/COMT_HUMAN", 
        "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016206", 
        "http://www.uniprot.org/uniprot/COMT_HORSE", 
        "http://www.uniprot.org/uniprot/COMT_BOVIN", 
        "http://www.disease-ontology.org/api/metadata/DOID:14330", 
        "http://www.uniprot.org/uniprot/COMT_PIG"
    ], 
    "type": "list", 
    "id": "51487ef9d24251bc05000031", 
    "snippets": [
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 215, 
            "text": "Entacapone is a highly potent, reversible, peripherally acting catechol-O-methyl transferase (COMT) inhibitor that is used as an adjunct to L-dopa in the treatment of patients with Parkinson disease (PD).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164341", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1251, 
            "offsetInEndSection": 1614, 
            "text": "Stalevo is a combination tablet comprised of levodopa, carbidopa, and the COMT inhibitor entacapone. It is available in fixed-dose combinations of levodopa/carbidopa/entacapone, 50/12.5/200, 75/18.75/200, 100/25/200, 125/31.25/200, 150/37.5/200 and 200/50/200 mg. Stalevo is currently approved for use in Parkinson's disease patients with end-of-dose wearing off.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19589043", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 306, 
            "offsetInEndSection": 637, 
            "text": "Good news were marketing of ropinirole, a new non-ergot agonist, in December 2006 and entacapone, the first catechol-O-methyl transferase (COMT) inhibitor in Japan in April 2007. Having faced these new situations, Japanese Neurological Association has started revising \"the Guideline 2002 for the treatment of Parkinson's disease\".", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19198095", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 620, 
            "offsetInEndSection": 776, 
            "text": "Stalevo (Orion) combines levodopa, the dopa-decarboxylase inhibitor carbidopa and the catechol-O-methyl transferase inhibitor entacapone in a single tablet.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15853578", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 250, 
            "text": "We investigated whether administration of the catechol-O-methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15372589", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 197, 
            "text": "The catechol-O-methyl transferase inhibitor entacapone is given in combination with levodopa/dopa decarboxylase inhibitor for Parkinson's disease (PD) patients experiencing end-of-dose wearing-off.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/14741081", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 325, 
            "text": "Entacapone (Comtess/Comtan) is Orion Pharma's original proprietary catechol-O-methyl transferase (COMT) inhibitor. Entacapone is able to slow down degradation of levodopa and improve the availability and efficacy of each levodopa dose, hence its use as a complement to levodopa/carbidopa in patients with Parkinson's disease.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12952501", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 77, 
            "text": "Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12588639", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 266, 
            "text": "We present a patient who suffered from sleep attacks after starting entacapone in addition to levodopa. Entacapone, a catechol-O-methyl transferase inhibitor, alters the pharmacokinetics of levodopa, leading to increase of levodopa concentration in plasma and brain.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12588639", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 160, 
            "offsetInEndSection": 273, 
            "text": "Two COMT inhibitors, tolcapone and entacapone, have recently been made available as adjunctive agents to levodopa", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11147512", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 185, 
            "text": "Two inhibitors of catechol-O-methyl transferase (COMT), tolcapone and entacapone, have recently been introduced as adjuncts to levodopa in the treatment of Parkinson's disease patients.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11147511", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1446, 
            "offsetInEndSection": 1569, 
            "text": "Tolcapone, a peripheral and central COMT inhibitor, appears to be quite effective, producing a 47% reduction in 'off' time.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10733264", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1761, 
            "offsetInEndSection": 1957, 
            "text": ". Entacapone, a purely peripheral COMT inhibitor with a lower potency than tolcapone, has also proved to be effective and has not been associated with liver damage, obviating the need for testing.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10733264", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 316, 
            "offsetInEndSection": 524, 
            "text": "Here we report that a treatment of the cerebral tissue with tolcapone, a central and peripheral inhibitor of COMT, does not change the membrane responses of midbrain dopamine neurons to dopamine and levodopa.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10651109", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 721, 
            "offsetInEndSection": 873, 
            "text": "Therefore, the therapeutic action of tolcapone in Parkinson's disease, might be dependent on the reduction of COMT activity in the extracerebral tissue.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10651109", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 294, 
            "offsetInEndSection": 568, 
            "text": "Pretreatment with entacapone (OR-611), a peripheral catechol O-methyl-transferase (COMT) inhibitor, greatly reduces the plasma 3OMFD fraction and provides an ideal situation to evaluate the contribution of the plasma 3OMFD fraction in several kinetic models of FDOPA uptake.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8784230", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 87, 
            "offsetInEndSection": 356, 
            "text": "The novel and reversible inhibitors are the catechol-O-methyl-transferase (COMT) inhibitors, Ro 40-7592 (3,4-dihydroxy-4'-methyl-5-nitrobenzophenone), and the monoamine oxidase type-B (MAO-B) inhibitor, Ro 19-6327 (N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide HC1).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/1933685", 
            "endSection": "sections.0"
        }
    ]
}